<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084396</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000361963</org_study_id>
    <secondary_id>R01CA095614</secondary_id>
    <secondary_id>P30CA091842</secondary_id>
    <secondary_id>WU-03-0586</secondary_id>
    <secondary_id>UCSF-02755</secondary_id>
    <secondary_id>UCSF-H8409-21398-04</secondary_id>
    <nct_id>NCT00084396</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer</brief_title>
  <official_title>A Phase 2 Trial Of 4 Months Preoperative Letrozole 2.5 mg Daily For Postmenopausal Women With Estrogen Receptor Positive And/Or Progesterone Receptor Positive T2, T3, T4a-c, N0-2, M0 Breast Cancer- Novel Biomarkers for Aromatase Inhibitor Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using&#xD;
      letrozole may fight breast cancer by reducing the production of estrogen. Giving letrozole&#xD;
      before surgery may shrink the tumor so that it can be removed.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well neoadjuvant letrozole works in treating&#xD;
      postmenopausal women who are undergoing surgery for estrogen-receptor positive or&#xD;
      progesterone-receptor positive stage II, stage IIIA, or stage IIIB breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Develop a predictive model of response (based on gene expression profiling) in&#xD;
           postmenopausal women with estrogen- and/or progesterone-receptor positive stage II,&#xD;
           IIIA, or IIIB breast cancer treated with neoadjuvant letrozole.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the response rate in patients treated with this drug.&#xD;
&#xD;
        -  Determine changes in Ki67 proliferation rates in patients treated with this drug.&#xD;
&#xD;
        -  Determine the rate of improvement in surgical outcomes in patients treated with this&#xD;
           drug.&#xD;
&#xD;
        -  Determine the long-term outcomes in patients treated with this drug.&#xD;
&#xD;
        -  Determine the safety of this drug in these patients.&#xD;
&#xD;
        -  Determine mechanisms of resistance to this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive neoadjuvant oral letrozole once daily for 16 weeks in the absence of disease&#xD;
      progression. Patients then undergo breast surgery one day after the last dose of letrozole.&#xD;
      Patients with partial response after 16 weeks may continue to receive letrozole for an&#xD;
      additional 8 weeks before undergoing breast surgery.&#xD;
&#xD;
      Patients are followed within 4 weeks after definitive surgery and then annually for 10 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 150 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Predictive model for response as assessed by gene expression profiling</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Ki67 proliferation rates</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of improvement in surgical outcomes</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term outcomes</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanisms of resistance</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Letrozole/Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <arm_group_label>Letrozole/Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <arm_group_label>Letrozole/Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed infiltrating adenocarcinoma of the breast by core needle&#xD;
             biopsy&#xD;
&#xD;
               -  Clinical stage T2-T4a-c, N0-2, M0&#xD;
&#xD;
          -  Palpable and measurable disease&#xD;
&#xD;
          -  Previously untreated disease&#xD;
&#xD;
          -  Benefits from neoadjuvant therapy that would improve surgical outcome AND meets&#xD;
             criteria for 1 of the following:&#xD;
&#xD;
               -  Marginal candidate for lumpectomy (e.g., lumpectomy feasible but patient at risk&#xD;
                  for positive margins or poor cosmetic outcome) AND patient desires&#xD;
                  breast-conserving surgery&#xD;
&#xD;
               -  Ineligible for lumpectomy due to size of primary tumor, but modified radical&#xD;
                  mastectomy feasible AND patient desires breast-conserving surgery&#xD;
&#xD;
               -  Inoperable disease AND systemic therapy required for disease to become operable&#xD;
                  by modified radical mastectomy&#xD;
&#xD;
          -  Bilateral primary tumors allowed provided both tumors are consistent with entry&#xD;
             criteria&#xD;
&#xD;
          -  No inflammatory carcinoma (defined as peau d' orange affecting at least one third of&#xD;
             the breast)&#xD;
&#xD;
               -  Direct extension of the tumor to the skin allowed&#xD;
&#xD;
          -  No metastatic breast disease, except isolated ipsilateral supraclavicular&#xD;
             lymphadenopathy&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen- and/or progesterone-receptor positive disease based on 10% or more&#xD;
                  nuclear staining of the invasive component of the tumor&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Postmenopausal&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Postmenopausal, defined as meeting 1 of the following criteria:&#xD;
&#xD;
               -  Cessation of menstrual periods for at least 1 year&#xD;
&#xD;
               -  Bilateral surgical oophorectomy&#xD;
&#xD;
               -  Follicle-stimulating hormone and estradiol levels in the postmenopausal range&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  No severe liver dysfunction that would preclude study participation&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Willing and able to provide biopsy material&#xD;
&#xD;
          -  Willing to undergo breast surgery after neoadjuvant treatment&#xD;
&#xD;
          -  No condition (e.g., confusion, infirmity, or alcoholism) that would preclude study&#xD;
             compliance&#xD;
&#xD;
          -  No other concurrent active and progressive invasive malignancies&#xD;
&#xD;
          -  No other concurrent severe disease that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy or biological response modifiers for breast cancer&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for breast cancer&#xD;
&#xD;
          -  No concurrent chemotherapy for breast cancer&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 2 weeks since prior hormone replacement therapy or phytoestrogenic herbal,&#xD;
             alternative, or over-the-counter (OTC) sex hormone remedies&#xD;
&#xD;
          -  No prior hormonal agents for breast cancer&#xD;
&#xD;
          -  No prior aromatase inhibitors, tamoxifen, raloxifene, or other antiestrogen or&#xD;
             selective estrogen receptor modulators&#xD;
&#xD;
          -  No concurrent drugs known to affect sex hormone status, including hormone replacement&#xD;
             therapy or phytoestrogenic herbal, alternative, or OTC remedies&#xD;
&#xD;
          -  No other concurrent endocrine therapy for breast cancer&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy for breast cancer&#xD;
&#xD;
          -  No concurrent radiotherapy for breast cancer&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Prior sentinel node biopsy allowed&#xD;
&#xD;
          -  No other concurrent surgery for breast cancer&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior non-approved or experimental drugs&#xD;
&#xD;
          -  Concurrent bisphosphonates for osteoporosis allowed&#xD;
&#xD;
          -  No other concurrent treatment for breast cancer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Naughton, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

